Indivior PLC/ GB00BN4HT335 /
2024-05-31 9:02:31 PM | Chg. +0.08 | Volume | Bid10:25:00 PM | Ask10:25:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
18.27USD | +0.44% | 764 Turnover: 7,310.50 |
-Bid Size: - | -Ask Size: - | 2.53 bill.USD | - | 1,841.24 |
GlobeNewswire
05-31
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire
04-18
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
04-11
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire
04-03
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire
03-05
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
01-31
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire
2023-11-23
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
Newsfile Corp
2023-10-31
Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland
GlobeNewswire
2023-09-06
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference